Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inactivated influenza vaccine + 23-valent pneumococcal polysaccharide vaccine
- Development stage
- Unknown
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
This drug entry refers to the co-administration of an inactivated influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine (PPV23), specifically as evaluated in a Phase II clinical trial (NCT00124111) sponsored by Memorial Sloan Kettering Cancer Center. The trial investigated the immunogenicity and safety of these vaccines in cancer patients aged 65 and older with prostate, lung, or breast cancer. The pneumococcal vaccine (e.g., Pneumovax 23) contains purified capsular polysaccharides from 23 serotypes of *Streptococcus pneumoniae*, while the inactivated influenza vaccine contains hemagglutinin antigens from seasonal strains. The goal of the regimen is to provide comprehensive protection against pneumonia, bacteremia, meningitis, and seasonal flu in high-risk oncology patients.
- Brand names
- Pneumovax 23Pneumovax23Pneumovax-23
- Other names
- PPV23 + IIVPneumovax + influenza vaccine
02
Targets
HA (Hemagglutinin)CPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on inactivated influenza vaccine + 23-valent pneumococcal polysaccharide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inactivated influenza vaccine + 23-valent pneumococcal polysaccharide vaccine.